The Case for Primary Prevention of Atherosclerotic Events from Study of a Single Patient

Area of Science:

• Cardiology
• Vascular Biology
• Preventive Medicine

Background:

• Atherosclerotic plaque formation is a primary cause of cardiovascular events.
• Current guidelines for lipid-lowering therapy focus on reducing event risk rather than plaque prevention.
• Unstable angina pectoris signifies a critical stage of atherosclerotic disease.

Observation:

• A 64-year-old woman with no prior atherosclerotic events presented with unstable angina pectoris.
• She required coronary artery bypass surgery with endarterectomy due to severe, diffuse atherosclerotic narrowing of the right coronary artery.
• Preoperatively, she did not meet existing criteria for lipid-lowering drug initiation.

Findings:

• The patient's presentation highlights a deficiency in current lipid-lowering drug guidelines.
• Existing guidelines may fail to identify individuals at high risk for plaque progression.
• Severe atherosclerotic disease can develop even in the absence of traditional risk factors or guideline indications.

Implications:

• There is a critical need to shift therapeutic emphasis from preventing atherosclerotic events to preventing arterial plaque formation.
• Initiating lipid-lowering therapy at a lower threshold of low-density lipoprotein cholesterol may be necessary for effective plaque prevention.
• Revised guidelines are needed to better address the prevention and management of atherosclerotic plaque disease.